Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![CAR T cells-GettyImages-2243155532]( "Target Selection Drives The Future Of CAR T Therapy In Solid Tumors")
Target Selection Drives The Future Of CAR T Therapy In Solid Tumors4/13/2026Target selection is the defining challenge in CAR T therapy for solid tumors, shaping safety, efficacy, and the field’s path forward.
-
![Car-T cell attacking cancer cell-GettyImages-2252478724]( "Mitigating Challenges In Solid Tumor Delivery")
Mitigating Challenges In Solid Tumor Delivery4/3/2026CAR T-cell therapy is advancing in solid tumors by improving target selection, trafficking, tumor-microenvironment resistance, and long-term function, but major biological barriers still require combined solutions.
-
![Female scientist microscope-GettyImages-1453524892]( "Ensuring Quality Of CGT Materials")
Ensuring Quality Of CGT Materials3/24/2026Here's why strong material selection, risk-based controls, and early analytics are critical for successful CGT development.
-
![medical chart, healthcare, medicine-GettyImages-2217159653]( "Building Harmonized Real‑World Data In Oncology")
Building Harmonized Real‑World Data In Oncology3/13/2026Experts at PMWC 2026 emphasized that regulatory‑grade real‑world data in oncology will require prospectively collected, harmonized datasets that integrate multimodal clinical information.
-
![T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy-GettyImages-1317697233]( "The In Vivo Cell Therapy Shift On Display At PMWC 2026")
The In Vivo Cell Therapy Shift On Display At PMWC 20263/10/2026At PMWC 2026 in Santa Clara, we saw how in vivo CAR T and MRD‑guided strategies could reshape cell therapy by moving curative intent earlier while balancing bold innovation with practical scalability.
-
![Rare diseases, medical-GettyImages-2183368270]( "Inside SynaptixBio's Mission To Develop A Therapy For H-ABC")
Inside SynaptixBio's Mission To Develop A Therapy For H-ABC3/9/2026SynaptixBio's Dr. Dan Williams discusses the company’s effort to develop an antisense oligonucleotide therapy that silences the mutant TUBB4A gene in the ultra-rare leukodystrophy H-ABC, highlighting the scientific, regulatory, and funding challenges of advancing treatments for extremely small patient populations.
-
![AI, artificial intelligence-GettyImages-2183748780]( "Powering AI And Synthetic Biology In Therapy Design")
Powering AI And Synthetic Biology In Therapy Design2/27/2026AI-driven cell therapies depend on high-quality, well-structured data to accelerate discovery, development, and clinical success.
-
![Mesenchymal stem cells MSCs, Medicinal signaling cells-GettyImages-2189923819]( "Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real")
Inside Mesoblast's Playbook For Making Allogeneic Cell Therapy Real2/18/2026Mesoblast's Silviu Itescu shares how two decades of rigorous science and manufacturing turned allogeneic MSCs into the first FDA-approved cell therapy while building a scalable platform for inflammatory diseases such as GvHD, back pain, and heart failure.
-
![Rising arrows scalability-gettyimage117247268]( "Disciplined CGT Will Win On 2026 Regulatory Flexibility")
Disciplined CGT Will Win On 2026 Regulatory Flexibility1/29/2026Wilson Bryan, M.D., and Daniela Drago, Ph.D., RAC, joined our our first Cell & Gene Live of 2026 to unpack what a more mature era of regulatory oversight means for sponsors.
-
![planning, progress, forward thinking-GettyImages-2245382606]( "ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026")
ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 20261/12/2026ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.
